Clinical Trials on Burned in Australia

Total 466 results

Kirby Institute
Hoffmann-La Roche

Completed

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study (ASK-500)

HIV Infections

Australia
Kirby Institute

Completed

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. (ENCORE1)

HIV Infections

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

HIV Infections

Australia
Kirby Institute

Recruiting

Real World Assessment of People Living With Chronic Hepatitis B in Australia (REACH-B)

Hepatitis B

Australia
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
Kirby Institute

Withdrawn

Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays

Hepatitis B

Australia
Kirby Institute
University of Public Health, Myanmar

Completed

Simplified Monitoring Myanmar SM2 Study (SM2)

HIV Infections | Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
Enyo Pharma
CPR Pharma Services Pty Ltd, Australia

Completed

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Hepatitis B, Chronic

Thailand, Netherlands, Australia, Poland
Kirby Institute

Completed

Raltegravir and Atazanavir Dosing Strategy Study (SPARTA)

HIV Infection

Australia
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Gilead Sciences; Hoffmann-La... and other collaborators

Terminated

Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

HIV Infections | HIV-Associated Lipodystrophy

Australia
Kirby Institute

Completed

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (SIMPLIFY)

Hepatitis C

Australia
Bayside Health

Terminated

Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

HIV Infections | Hepatitis C

Australia
Holdsworth House Medical Practice

Completed

RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice

HIV Positive

Australia
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Pfizer

Completed

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Encephalitis, Tick-Borne

Austria, Czechia
University of Dundee
Burnet Institute; Public Health Wales

Completed

Reaching mEthadone Users Attending Community pHarmacies With HCV (REACH HCV)

Hepatitis C

Australia, United Kingdom
407 Doctors
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Unknown

Once Daily 3TC, Efavirenz and ddI for HIV Infection

HIV Infection | AIDS

Australia
Pfizer

Completed

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

Encephalitis, Tick-Borne

Austria, Germany, Poland
Kirby Institute

Completed

Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C)

Hepatitis C

Australia
GlaxoSmithKline

Completed

Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared

Hepatitis B | Hepatitis A

Australia, Belgium, Spain
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
Arrowhead Pharmaceuticals

Completed

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Hepatitis B

Australia, Hong Kong, New Zealand
Bristol-Myers Squibb

Terminated

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Hepatitis C | Chronic Hepatitis

Australia, Spain
Garvan Institute of Medical Research

Completed

Chronic Hepatitis C and Insulin Resistance

Hepatitis C | Insulin Resistance

Australia
University of Modena and Reggio Emilia

Completed

Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles (Aging_in_HIV)

HIV Infection | Aging

Australia, Italy, Spain
GlaxoSmithKline

Completed

Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine

Hepatitis B | Hepatitis A

Australia
Kirby Institute

Recruiting

Evaluation of Hepatitis B Virus (HBV) DNA Test as Point of Care Tool (HBVPOCT)

Hepatitis B

Australia
St Vincent's Hospital Melbourne
Merck Sharp & Dohme LLC

Unknown

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6)

Chronic Hepatitis C

Australia
Pfizer

Completed

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Encephalitis, Tick-borne

Austria
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Kirby Institute
AbbVie

Completed

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

Hepatitis C, Acute

United Kingdom, Australia, New Zealand
GlaxoSmithKline

Completed

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

Hepatitis B

Australia, Belgium
Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C

Australia
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Kirby Institute

Active, not recruiting

Control and Elimination Within Australia of Hepatitis C From People Living With HIV (CEASE)

Hepatitis C | HIV | HIV-HCV Coinfection

Australia
Themis Bioscience GmbH

Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Zika Virus

Austria
Themis Bioscience GmbH

Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) (MV-ZIKA-RSP)

Zika Virus Infection

Austria
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
Medical University of Graz

Recruiting

Work-Health-Life-Balance - Mental Resilience, Stability & Healthy Nutrition

Depressive Disorder | Sleep | Psychological Stress | Nutritional Quality | Burn-out Syndrome

Austria
Medical University of Vienna

Unknown

The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (RemiSun 1)

Hyperalgesia

Austria
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

Hepatitis B

Austria
Medical University of Vienna

Unknown

The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)

Hyperalgesia

Austria
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID); Monash University and other collaborators

Completed

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

HIV | Human Immunodeficiency Virus

United States, Australia
Kirby Institute
The Alfred; Peter MacCallum Cancer Centre, Australia; St Vincent's Hospital; Monash... and other collaborators

Active, not recruiting

Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) (ARCHIVE)

HIV Infections | Aging

Australia
Kirby Institute
Merck Sharp & Dohme LLC; The University of New South Wales

Completed

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients (SEARCH-C)

Chronic Hepatitis C Infection

Australia
Kirby Institute
Gilead Sciences; The University of New South Wales

Completed

Tenofovir in HIV/HBV Coinfection (TICO)

HIV Infection | Hepatitis B Coinfection

Australia, Thailand
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Hoffmann-La Roche

Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

HIV Infections

Australia
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia

3

Subscribe